LivaNova PLC $LIVN Shares Acquired by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in LivaNova PLC by 13.4%, now owning 126,266 shares valued at approximately $4.96 million.
• Analysts have raised their ratings on LivaNova, with Wolfe Research upgrading it to "outperform" and several target prices now ranging from $58.00 to $64.00.
• LivaNova reported a quarterly earnings per share of $1.05, exceeding analysts' expectations, with a revenue of $352.50 million during the quarter.

Invesco Ltd. increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 13.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 126,266 shares of the company's stock after purchasing an additional 14,892 shares during the period. Invesco Ltd. owned 0.23% of LivaNova worth $4,960,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Freestone Grove Partners LP purchased a new stake in shares of LivaNova in the fourth quarter worth about $23,102,000. The Manufacturers Life Insurance Company lifted its position in LivaNova by 163.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock worth $25,303,000 after acquiring an additional 339,139 shares in the last quarter. AQR Capital Management LLC boosted its holdings in LivaNova by 79.3% in the 4th quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock worth $34,214,000 after acquiring an additional 328,313 shares during the period. LSV Asset Management grew its position in LivaNova by 278.3% in the first quarter. LSV Asset Management now owns 438,498 shares of the company's stock valued at $17,224,000 after acquiring an additional 322,598 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of LivaNova by 13.5% during the first quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock valued at $104,755,000 after purchasing an additional 316,993 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Performance

Shares of LIVN stock traded up $0.12 on Tuesday, hitting $56.49. 17,850 shares of the stock traded hands, compared to its average volume of 700,956. The company's fifty day moving average is $47.75 and its 200 day moving average is $43.35. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $57.35. The company has a market capitalization of $3.08 billion, a PE ratio of -14.52 and a beta of 0.96. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.21. The firm had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.93 earnings per share. On average, equities research analysts predict that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Robert W. Baird upped their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Needham & Company LLC reissued a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research report on Tuesday, May 13th. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a research note on Tuesday, May 20th. Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, Barclays increased their price target on LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, LivaNova currently has an average rating of "Buy" and an average price target of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.